InspireMD (NSPR) risk factors
Item 1A of every InspireMD, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors58 risks16 new7 dropped11 reworded
The risk section is dominated by the recent US commercial launch of CGuard Prime and upcoming trials for SwitchGuard NPS. Increased disclosures focus on US sales execution, clinical trial compliance, single-source component vulnerabilities, and Israeli operational dependencies.
Filed Mar 18, 2026 - FY2024 10-K risk factors49 risks
InspireMD reports recurring net losses, including $32.0 million for 2024, and holds an accumulated deficit of $254 million. The company relies heavily on the success, FDA approval, and self-commercialization of the CGuard Prime carotid stent system. Operations in Israel expose the company to regional geopolitical conflicts and currency exchange risks.
Filed Mar 12, 2025